Solid Biosciences is trading 6.4% down now at $8.15 after releasing second-quarter results after the August 6 session, with investors appearing focused on widening losses and higher operating spending.
- Quarterly net loss rose to $54.8 million from $39.5 million a year earlier.
- Research and development expenses increased to $44.3 million.
- Quarterly EPS was $0.38, compared with the $0.46 estimate.